Biotechnology in China

Biotechnology in China

Category : Pharmaceuticals
November  2016  Pages : 33



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com
Summary
Biotechnology in China industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis
- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the biotechnology market in China

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the biotechnology market in China

- Leading company profiles reveal details of key biotechnology market players' global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the China biotechnology market with five year forecasts

Reasons To Buy
- What was the size of the China biotechnology market by value in 2016?

- What will be the size of the China biotechnology market in 2021?

- What factors are affecting the strength of competition in the China biotechnology market?

- How has the market performed over the last five years?

- What are the main segments that make up China's biotechnology market?

Key Highlights
The biotechnology market consists of the development, manufacturing, and marketing of products based on advanced biotechnology research.

The Chinese biotechnology market is expected to generate total revenues of $18.5bn in 2016, representing a compound annual growth rate (CAGR) of 8.4% between 2012 and 2016.

The Medical/Healthcare segment is expected to be the market's most lucrative in 2016, with total revenues of $18.1bn, equivalent to 97.8% of the market's overall value.

The Chinese government is seeking to help the domestic biotechnology industry through the creation of biotech zones and preferential regulations to locally produced drugs. It is hoped this will move Chinese companies away from cheap, generic drugs.
Table Of Contents
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Novo Nordisk A/S
Shanghai Kehua Bio-engineering Co., Ltd
Sinovac Biotech Ltd.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine


List Of Tables
Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Novo Nordisk A/S
Shanghai Kehua Bio-engineering Co., Ltd
Sinovac Biotech Ltd.
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine


List Of Figures
Figure 1: China biotechnology industry value: $ million, 2012-16(e)
Figure 2: China biotechnology industry category segmentation: % share, by value, 2016(e)
Figure 3: China biotechnology industry geography segmentation: % share, by value, 2016(e)
Figure 4: China biotechnology industry value forecast: $ million, 2016-21
Figure 5: Forces driving competition in the biotechnology industry in China, 2016
Figure 6: Drivers of buyer power in the biotechnology industry in China, 2016
Figure 7: Drivers of supplier power in the biotechnology industry in China, 2016
Figure 8: Factors influencing the likelihood of new entrants in the biotechnology industry in China, 2016
Figure 9: Factors influencing the threat of substitutes in the biotechnology industry in China, 2016
Figure 10: Drivers of degree of rivalry in the biotechnology industry in China, 2016
Figure 11: Novo Nordisk A/S: revenues and profitability
Figure 12: Novo Nordisk A/S: assets and liabilities
Figure 13: Shanghai Kehua Bio-engineering Co., Ltd: revenues and profitability
Figure 14: Shanghai Kehua Bio-engineering Co., Ltd: assets and liabilities
Figure 15: Sinovac Biotech Ltd.: revenues and profitability
Figure 16: Sinovac Biotech Ltd.: assets and liabilities

Enquiry Before Buy
image
Can´t read the image ? refresh here.